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Replication is a key to resolving whether a
reported genetic association represents a false
positive finding or an actual genetic risk factor.
In a previous study screening 51 candidate genes
for association with ADHD in a multi-centre
European sample (the IMAGE project), two
single nucleotide polymorphisms (SNPs) within
the norepinephrine transporter (SLC6A2) gene
were found to be associated with attention deficit
hyperactivity disorder (ADHD). The same SNP
alleles were also reported to be associated with
ADHD in a separate study from the Massachusetts
General Hospital in the US. Using two indepen-
dent samples of ADHD DSM-IV combined subtype
trios we attempted to replicate the reported
associations with SNPs rs11568324 and rs3785143
in SLC6A2. Significant association of the two
markers was not observed in the two independent
replication samples. However, across all four
datasets the overall evidence of association with
ADHD was significant (for SNP rs11568324
P¼0.0001; average odds ratio¼0.33; for SNP
rs3785143 P¼0.008; average odds ratio¼1.3). The
data were consistent for rs11568324, suggesting
the existence of a rare allele conferring protection
for ADHD within the SLC6A2 gene. Further
investigations should focus on identifying the
mechanisms underlying the protective effect.
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INTRODUCTION
The gene encoding the norepinephrine transporter
(SLC6A2, Gene ID: 6530, formerly known as NET1) is a strong
candidate for genetic association with attention deficit hyper-
activity disorder (ADHD). The norepinephrine neurotransmit-
ter system is thought to play a key role in attentional processes
and potentially in ADHD. Atomoxetine, a specific noradrener-
gic reuptake inhibitor is an effective treatment for ADHD,
although the slow time course of action suggests that indirect
mechanisms are involved in the therapeutic response. Atom-
oxetine leads to an overall increase in norepinephrine release
in the brain especially in the pre-frontal cortex with no
reported increases found in other areas of the brain implicated
in ADHD such as the striatum. Furthermore the norepinephr-
ine transporter appears to mediate the main part of the
reuptake of synaptic dopamine in the frontal cortex.
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Several groups have investigated the association of ADHD
with genetic variants of the SLC6A2 gene, which is located on
the long arm of chromosome 16. The initial association studies
proved negative although only a limited number of SNPs were
investigated and these studies failed to screen common genetic
variation spanning the entire gene. Xu et al. [2005] were the
first to provide a more comprehensive screen of SLC6A2. Using
a DNA pooling approach to scan 21 SNPs spanning the gene
they identified a SNP rs3785157 showing nominal signifi-
cance for association with ADHD in 180 ADHD probands from
the UK (nominal P¼ 0.04). They also found a trend association
for SNP rs998424 (P¼ 0.07). A subsequent report also reported
association of ADHD with rs3785157 and rs998424 [Bobb
et al., 2005], however the associated alleles were found to be the
opposite of that reported in the previous study. An additional
study reported a novel promoter SNP (3081A/T) to be
associated with ADHD [Kim et al., 2006].
More recently the gene was investigated in a study of 51
candidate genes in a European collaborative sample collected
by the International Multi-centre ADHD Genetics (IMAGE)
project [Brookes et al., 2006]. A total of 23 SNPs in SLC6A2
were investigated and two novel SNP associations were
identified showing nominal significance for association with
ADHD: rs3785143 located in intron 1 and rs11568324 located
in intron 5. Further support for association with the same two
SNPs has subsequently come for the analysis of 24 SNPs in a
sample of 474 ADHD probands collected at the Massachusetts
General Hospital in the United States [Kim et al., 2007]. Only
the two SNP alleles associated with ADHD in the IMAGE
sample showed significance in this study, constituting a direct
replication.
To establish whether this finding could be further replicated
we have genotyped the two associated markers in two
additional datasets from the IMAGE collaborative project
sample and from Dublin using a within family test of
association. We further report on the combined analysis of all
four independent samples that have analyzed the association
between ADHD and the two SNPs to date.
METHODS
IMAGE ST2 Sample
European Caucasian subjects were recruited from 12
specialist clinics in eight countries: Belgium, Germany, Hol-
land, Ireland, Israel, Spain, Switzerland, and United King-
dom. Ethical approval for the study was obtained from
National Institute of Health registered ethical review boards
for each centre. Detailed information sheets were provided and
informed consent obtained from the majority of children and
from all of their parents. All ADHD probands and their siblings
were aged 5–17 at the time of entry into the study and access
was required to one or both biological parents for DNA
collection. Entry criteria for probands were a clinical diagnosis
of DSM-IV combined subtype ADHD and having one or more
full siblings available for ascertainment of clinical information
and DNA collection. Exclusion criteria applying to both
probands and siblings included autism, epilepsy, IQ< 70,
brain disorders and any genetic or medical disorder associated
with externalizing behaviors that might mimic ADHD.
Inclusion criteria included white European ancestry and living
at home with at least one biological parent.
The diagnosis of ADHD was made following a parent
interview with the Parental Account of Child Symptoms
[PACS; Taylor et al., 1986] that asks about ADHD symptoms
in various settings. An algorithm was used to derive each of the
DSM-IV ADHD symptoms from the PACS interview data and
these were combined with items that scored 2 or more from
teacher ratings of DSM-IV items taken from the long version
of the Conners’ Teacher Rating Scale [Conners, 2003]. The
diagnosis of ADHD was made if sufficient items were identified
to fulfill DSM-IV criteria, and both impairment (based on
severity of symptoms identified in the PACS interview) and
pervasiveness (based on the presence of ADHD symptoms in
more than one setting from PACS and scoring more than one
item on the teacher Connors) were present. In 28 cases where
no Connors data was present pervasiveness was defined on the
basis of PACS data alone. More information on the clinical
evaluation of the ADHD probands and the stage 1 (ST1) sample
can be found in Brookes et al. [2006].
In this report we include new data from the IMAGE stage 2
sample (ST2) that consists of 435 combined type ADHD cases,
including 376 probands and 59 of their affected siblings, with
both parents present for 290 of the ADHD probands and only
the mother included for 77 of the probands. Following the
accumulation of further clinical information and a compre-
hensive audit of the entire clinical and DNA datasets
completed in April 2007, the final set of individuals with
combined type ADHD and fulfilling all inclusion and exclusion
criteria in ST1 and ST2 was amended. The final combined
ST1 and ST2 dataset used in this report consists of 1,147
individuals with DSM-IV combined subtype ADHD cases
consisting of 988 affected probands and 159 of their affected
siblings.
Dublin Sample
Two hundred twenty-two families with clinically diagnosed
ADHD children were recruited from child guidance clinics and
ADHD support groups around Ireland. The sample selection
and clinical procedures for this sample are described in detail
in Kirley et al. [2004]. The ages of ADHD probands were
between 4 and 17. Exclusion criteria included epilepsy, fragile
X syndrome, fetal alcohol syndrome, pervasive developmental
disorder, Tourettes syndrome and psychosis, IQ< 70). To
confirm DSM-IV diagnoses of ADHD, one or both parents of
each child were interviewed using the child and adolescent
psychiatric assessment (CAPA) [Angold et al., 1995]. To fulfill
ICD-10 and DSM-IV ADHD criteria for symptom pervasive-
ness, information about ADHD symptoms at school was
obtained from teachers using a semi-structured teacher tele-
phone interview which involved asking the class teacher about
DSM-IV symptoms of ADHD and impairment shown in class.
DSM-IV diagnostic criteria were then applied using the parent
and teacher interview data to derive the ADHD diagnostic
subtypes.
Control Sample
In this study 382 controls of Northern European ancestry
were genotyped for rs11568324. The controls were collected
from southeast England as part of a separate study of neuro-
cognitive endophenotypes [Kuntsi et al., 2006] and consisted
of the parents of child twin pairs who were unselected for
phenotype and fulfilled the same age, IQ and exclusion criteria
as the IMAGE clinical sample.
Genotyping and Statistical Analysis
The SNP markers rs11568324 and rs3785143 were included
in a 48-SNP multiplex designed by Applied Biosystems (ABI,
Foster City, US) as part of their SNPlex chemistry for
genotyping. Additional genotyping was performed using the
ABI TaqMan protocol under standard conditions provided by
ABI with a pre-designed TaqMan1 SNP genotyping Assay
(Assay ID: C_43668146_10). Genotyping for the samples from
Dublin were performed on a commercial platform by KBio-
sciences (Hoddesdon, UK). Genotype data were analyzed using
the UNPHASED software (www.mrc.cam.ac.uk/personal/
frank/software/unphased) with implementation of the option
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to handle missing parental genotypes for the ST1 and ST2
samples. The Dublin samples included analysis of complete
trios only.
RESULTS
The transmission disequilibrium test results are presented
in Table I. For rs11568324, genotyping was successful for
98.3% of the ST2 sample and 93% of the Dublin sample. The
T allele for this marker was previously found to have a
low minor allele frequency (MAF) of around 1% and a similar
MAF was observed in both samples with genotypes also in
Hardy–Weinberg equilibrium (HWE). In both the IMAGE ST2
and Dublin samples the T allele was under-transmitted from
heterozygote parents to their affected offspring with similar
odds ratios to that observed in the previous two studies;
although neither findings were significant on their own (ST2:
w2¼ 2.57, P¼ 0.10; Dublin: w2¼ 2.0, P¼ 0.20).
For rs3785143 genotyping was successful in 88% of the ST2
sample and 89% of the Dublin sample. Despite the relatively
low call rates the data were included because the MAF was
similar in the ST2 sample to that seen in the ST1 sample
(around 10%) and genotypes were in HWE. In the Dublin
sample the minor allele frequency was 9% and the genotypes
were also in HWE. The results for rs3785143 did not replicate
the original data reported, with no evidence of over trans-
mission of the previously identified risk allele in either
sample.
Combined Analysis
To clarify the evidence for association from the four available
studies we completed a combined TDT analysis for the two
markers. For rs11568324 each of the four studies found similar
odds ratios with the rare T allele being transmitted in 17 out of
49 informative transmissions, indicating moderately strong
evidence of association with an overall odds ratio of 0.34
(nominal P¼ 8 105). We further completed the analysis
using only the complete parent-proband trios from the ST1 and
ST2 samples. The data were comparable (ST1: 3T:15NT,
P< 0.005, OR¼ 0.20; ST2: 4T:9NT, P< 17, OR¼ 0.44) with
an overall significance in the combined analysis of 6.1 105.
Due to the possibility of transmission distortion at this locus
or the recognized bias for association with major alleles that
results from genotyping errors when using the TDT [Adele
et al., 2003] we genotyped an additional set of Northern
European controls ascertained from southeast England and
compared these to allele frequency data that we had for the
two IMAGE samples and the Dublin sample. These data
are presented in Table II and show that for each of the
three samples as well as the overall combination there was
evidence for the association in the case control data that was
comparable to that obtained from the TDT analysis.
The more frequent rs3785143 did not show consistent effect
sizes across the four studies although overall there was a
nominally significant transmission of the minor allele to
affected offspring with an average odds ratio of 1.3 (P¼ 0.008).
Finally we considered haplotype analysis. The two markers
are part of the same haplotype block according to the D0
statistic (D0 ¼ 1.00 for transmitted alleles, D0 ¼ 0.65 for non-
transmitted alleles). However, due to the marked difference in
their allele frequencies they were not strongly correlated with
each other (r2¼ 0.01 for transmitted alleles, r2¼ 0.03 for
non-transmitted alleles). The two markers are therefore not
tagging each other and due to the very low MAF of rs11568324
no additional information was gained from the analysis of the
haplotype compared to the single marker data (data available
upon request).
DISCUSSION
The data from SNP rs11568324 in SLC6A2 provide good
evidence for association with ADHD. SNP rs11568324 is
located in intron 5 and is relatively rare with a minor allele
frequency of 1%. Although the rare allele was not found to be
significantly under transmitted in the ST2 and Dublin samples
the estimated odds ratios were very close to those previously
observed in the ST1 and MGH studies. Furthermore, when
the data from the four datasets were combined the overall
significance for this finding was considerable with an overall
significance level of 8 105 and combined odds ratio of 0.34.
Confirmation of this finding requires a significance level that
reaches genome-wide levels in the region of 7 108, requiring
the analysis of additional datasets [Dudbridge and Gusnanto,
2008]. Nevertheless, the data presented here indicate that the
rare T allele of rs11568324 is likely to confer protection for
ADHD. While this finding suggests an important role for the
noradrenergic transporter in the neuronal processes under-
lying ADHD, the very low frequency of the minor allele means
that the association has limited relevance to clinical practice.
Since the T allele has a frequency of no more than 1% in the
population it is particularly important to exclude potential
biases in the data that could lead to a misleading set of findings.
A chief candidate for such problems is genotyping error since it
would only take a limited number of changes to the trans-
mission ratio to have a dramatic impact on the significance
value and effect size for such a rare allele. This could occur for
example if the genotype assays failed to observe the rare T
allele in some individuals [Adele et al., 2003]. This is however
thought to be unlikely in this case since all four studies used
very different genotyping platforms, did not find Mendelian
errors in evaluating parent–offspring relationships and each
reported similar effect sizes for the association with odds ratio
of 0.28, 0.40, 0.31, and 0.33 in the respective studies. The allele
frequency observed in each of the four studies is also very
similar to that reported in the CEU HapMap panel of 0.008
(http://www.hapmap.org/). Furthermore, the findings were
supported in the comparison of case with control allele
frequencies, although the allele frequency of 1.44% was higher
than that reported in the HapMap panel and the relatively
TABLE I. Summary of TDT Data From the IMAGE Stage I (ST1) and Stage II (ST2); and the Massachusetts General Hospital (MGH)
and Dublin samples
Sample N trios
rs11568324 rs3785143
Allele T NT P value OR Allele T NT P value OR
ST1 752 T 5 19 0.004 0.26 T 133 95 0.02 1.40
ST2 435 T 6 11 0.22 0.54 T 28 30 0.80 0.93
MGH 474 T 4 13 0.03 0.31 T 93 64 0.02 1.45
Dublin 222 T 2 6 0.16 0.33 T 29 34 0.62 0.85
TOTAL 1,843 T 17 49 0.00008 0.34 T 283 223 0.008 1.27
T, transmitted alleles from heterozygous parents; NT, non-transmitted alleles from heterozygous parents; OR, odds ratio.
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small sample size for the controls indicates that some caution
must be taken drawing firm conclusions from this analysis.
Finally, in both the IMAGE ST1 sample [Brookes et al., 2006]
and the MGH study [Kim et al., 2007] rs11568324 was one of
only two nominally associated findings from the analysis of 40
and 24 SNPs spanning SLC6A2 in the respective studies. The
next steps are to further substantiate the evidence for
association of rs11568324 with ADHD and investigate the
functional mechanisms involved in the protective effect of the
rare T allele.
In addition to the association with rs11568324 in intron 5 we
also investigated the association of ADHD with rs3785143
located in intron 1. The evidence for association with this SNP
is less striking since the two new studies presented here did not
replicate the previous findings reported in the IMAGE ST1 and
MGH studies. Nevertheless, the combined analysis did not
exclude the association of the T allele of rs3785143 (P< 0.01)
and this remains a potential candidate requiring further data
to confirm or refute this finding.
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